



**Hertfordshire and
West Essex**
Integrated Care Board

NHS Herts and West Essex

Integrated Care Board (ICB)

Virulite Cold Sore Machine

July 2022 V1.0

Version Number	V1.0
Approved By	NHS Hertfordshire & West Essex Integrated Care Board.
Date Approved	1ST July 2022
Responsible Director	Medical Director
Directorate	Clinical
Staff Audience	HWE EBI and IFR Team, Primary and Secondary Care Clinicians, Provider Clinical Funding Teams
Publication Date	1st July 2022
Review Date	1st July 2024
Description	Policy for local Evidence Based Interventions procedure
Superseded Documents (if applicable)	Hertfordshire CCG (Priorities Forum) – Virulite Cold Sore Machine

Document Owner: Medical Directorate	Prepared by: Associate Medical Director for Planned Care and Prioritisation	First Published: 1 st July 2022
Document number:	Approval date: 1 st July 2022	Version number: 1.0
Status: Approved	Next review date: 1 st July 2024	

Document Control

Version	Page	Details of amendment	Author

Document Owner: Medical Directorate	Prepared by: Associate Medical Director for Planned Care and Prioritisation	First Published: 1 st July 2022
Document number:	Approval date: 1 st July 2022	Version number: 1.0
Status: Approved	Next review date: 1 st July 2024	

The policy should include a contents page, as set out below, and be structured around all of the headings shown (although not necessarily in the same order)

CONTENTS

Section		Page
1.	Introduction An overview of the importance of the policy	4
2.	Purpose The rationale for the development of the policy; objectives and intended outcomes of the process / system described	4
3.	Content The key points of the policy should be written in a clear, concise manner, so as to be easily understood and correctly interpreted	4

Appendices:

Each appendix will be numbered to follow on from the policy document.

Document Owner: Medical Directorate	Prepared by: Associate Medical Director for Planned Care and Prioritisation	First Published: 1 st July 2022
Document number:	Approval date: 1 st July 2022	Version number: 1.0
Status: Approved	Next review date: 1 st July 2024	

Policy: Virulite Cold Sore Machine

The Virulite Cold Sore Machine works by emitting light of a wavelength that its developers claim heals cold sores twice as quickly as using an antiviral cream.

Following a number of refinements to the device and two clinical trials, Virulite CS has now been accepted as an addition to part IX of the Drug Tariff for England and Wales, (and part 3 of the Scottish Drug Tariff), prescribable on the NHS from 1 January 2008.

Virulite costs £18.50 per machine and they carry a three-year warranty.

The evidence for the effectiveness of these machines either against placebo or topical aciclovir is very limited and no long-term safety data could be found on a search. The evidence relates to crusting or healing rates and not to prevention of recurrence or to use in combination with other treatments.

NHS Clinical Knowledge Summaries states that the benefits of topical antivirals (aciclovir or penciclovir) are small and require treatment to be initiated at the onset of symptoms (erythema or prodromal stage) before vesicles appear. They do not recommend that oral antivirals should be used in immunocompetent individuals for mild-to-moderate episodes given the self-limiting nature of the disease, the limited benefits of oral antivirals, and that treatment needs to be initiated at the onset of prodromal symptoms. They may be of most use in severe cases or in immunocompromised individuals at risk of developing further complications.

In terms of any one specific patient, prescribing the Virulite might be an option if an immunocompetent patient is unable to concord with the usual self-help advice and the administration schedules for more established therapies or is frequently presenting for repeat prescriptions. However, that this product should NOT be prescribed routinely for herpes labialis until such time more robust evidence of benefit is available.

The Human Rights Act has been considered in the formation of this policy statement

Patients who are not eligible for treatment under this policy may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. Individual cases will be reviewed as per the ICB policy.

Document Owner: Medical Directorate	Prepared by: Associate Medical Director for Planned Care and Prioritisation	First Published: 1 st July 2022
Document number:	Approval date: 1 st July 2022	Version number: 1.0
Status: Approved	Next review date: 1 st July 2024	